Key statistics
On Friday, Aprea Therapeutics Inc (APRE:NAQ) closed at 0.6094, 11.20% above the 52 week low of 0.548 set on Jan 29, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 0.5868 |
|---|---|
| High | 0.6439 |
| Low | 0.561 |
| Bid | 0.5803 |
| Offer | 0.61 |
| Previous close | 0.5927 |
| Average volume | 572.12k |
|---|---|
| Shares outstanding | 6.99m |
| Free float | 5.35m |
| P/E (TTM) | -- |
| Market cap | 4.26m USD |
| EPS (TTM) | -2.14 USD |
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
More ▼
Announcements
- Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth
- Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor
- Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan
- Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules
- Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026
- Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules
- Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update
- Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051
- Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies
- Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
More ▼
